文献速递精神分裂症与精神病性障碍

精神病临床高风险个体脑形态学的常模建模研究

Normative Modeling of Brain Morphometry in Clinical High Risk for Psychosis.
PubMed 文献 · JAMA Psychiatry · 2024-01-01

该病例对照研究纳入1340例精神病临床高风险个体与1237名健康人,比较皮质厚度、表面积及皮质下体积的常模偏离分数。结果显示两组分布高度重叠,偏离超常范围的比例均低;仅表面积平均偏离分数与阳性症状及IQ相关,结论认为宏观脑形态学指标不足以解释精神病风险。

要点

  • 精神病临床高风险个体与健康人的脑形态学测量值分布高度重叠。
  • 单个脑区偏离常模范围的个体比例在两组中均较低且相近。
  • 仅表面积平均偏离分数与阳性症状及IQ存在小幅关联。

核心结论

  • 宏观神经形态学测量可能不足以充分解释精神病临床高风险个体的精神病风险。

研究设计与样本

  • 病例对照研究,纳入1340例精神病临床高风险个体和1237名健康人,数据来自29个国际站点,按年龄和性别匹配。

主要发现

  • 精神病临床高风险个体与健康人在观察值、区域z分数及所有平均偏离分数上分布重叠。
  • 任一脑区中,精神病临床高风险个体出现低于或高于常模范围的比例较低(最多153人,<11.42%),与健康人(<115人,<9.30%)相近。
  • 转化为精神病性障碍的精神病临床高风险个体在颞叶区域低于常模值的比例高于未转化者(7.01% vs 1.38%)及健康人(5.10% vs 0.89%)。
  • 在精神病临床高风险组中,仅表面积平均偏离分数与阳性症状(β=-0.08;95%CI,-0.13至-0.02;P=.02,FDR校正)及IQ(β=0.09;95%CI,0.02至0.15;P=.02,FDR校正)相关。

临床怎么用

  • 临床评估精神病临床高风险个体时,不宜依赖宏观脑形态学测量作为风险判断的主要依据。
  • 对于精神病临床高风险个体,颞叶区域形态学偏离或可作为转化风险的参考线索,但需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The lack of robust neuroanatomical markers of psychosis risk has been traditionally attributed to heterogeneity. A complementary hypothesis is that variation in neuroanatomical measures in individuals at psychosis risk may be nested within the range observed in healthy individuals. OBJECTIVE: To quantify deviations from the normative range of neuroanatomical variation in individuals at clinical high risk for psychosis (CHR-P) and evaluate their overlap with healthy variation and their association with positive symptoms, cognition, and conversion to a psychotic disorder. DESIGN, SETTING, AND PARTICIPANTS: This case-control study used clinical-, IQ-, and neuroimaging software (FreeSurfer)-derived regional measures of cortical thickness (CT), cortical surface area (SA), and subcortical volume (SV) from 1340 individuals with CHR-P and 1237 healthy individuals pooled from 29 international sites participating in the Enhancing Neuroimaging Genetics Through Meta-analysis (ENIGMA) Clinical High Risk for Psychosis Working Group. Healthy individuals and individuals with CHR-P were matched on age and sex within each recruitment site. Data were analyzed between September 1, 2021, and November 30, 2022. MAIN OUTCOMES AND MEASURES: For each regional morphometric measure, deviation scores were computed as z scores indexing the degree of deviation from their normative means from a healthy reference population. Average deviation scores (ADS) were also calculated for regional CT, SA, and SV measures and globally across all measures. Regression analyses quantified the association of deviation scores with clinical severity and cognition, and 2-proportion z tests identified case-control differences in the proportion of individuals with infranormal (z < -1.96) or supranormal (z > 1.96) scores. RESULTS: Among 1340 individuals with CHR-P, 709 (52.91%) were male, and the mean (SD) age was 20.75 (4.74) years. Among 1237 healthy individuals, 684 (55.30%) were male, and the mean (SD) age was 22.32 (4.95) years. Individuals with CHR-P and healthy individuals overlapped in the distributions of the observed values, regional z scores, and all ADS values. For any given region, the proportion of individuals with CHR-P who had infranormal or supranormal values was low (up to 153 individuals [<11.42%]) and similar to that of healthy individuals (<115 individuals [<9.30%]). Individuals with CHR-P who converted to a psychotic disorder had a higher percentage of infranormal values in temporal regions compared with those who did not convert (7.01% vs 1.38%) and healthy individuals (5.10% vs 0.89%). In the CHR-P group, only the ADS SA was associated with positive symptoms (β = -0.08; 95% CI, -0.13 to -0.02; P = .02 for false discovery rate) and IQ (β = 0.09; 95% CI, 0.02-0.15; P = .02 for false discovery rate). CONCLUSIONS AND RELEVANCE: In this case-control study, findings suggest that macroscale neuromorphometric measures may not provide an adequate explanation of psychosis risk.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Haas SS, Ge R, Agartz I, et al. Normative Modeling of Brain Morphometry in Clinical High Risk for Psychosis. JAMA Psychiatry. 2024. PMID: 37819650. doi:10.1001/jamapsychiatry.2023.3850

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。